BBA
LCTX icon

Braun-Bostich & Associates’s Lineage Cell Therapeutics LCTX Stock Holding History

Braun-Bostich & Associates’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2
Closed – – 202
2019
Q2 		$0 Hold
2
– – ﹤0.01% 324
2019
Q1 		$0 Buy
+2
New +$2 ﹤0.01% 333

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Braun-Bostich & Associates's LCTX Position: Q3 2019 in Review

Braun-Bostich & Associates sold out of Lineage Cell Therapeutics (LCTX) in Q3 2019, closing a stake of 2 shares.

Braun-Bostich & Associates first reported a position in LCTX in Q1 2019 and held it in 2 quarters. The position peaked at $0 in Q2 2019. 96 funds tracked by Wall St. Rank hold LCTX as of Q3 2019.

  • Braun-Bostich & Associates reported no remaining Lineage Cell Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Braun-Bostich & Associates sold 2 Lineage Cell Therapeutics shares in Q3 2019.
  • Braun-Bostich & Associates first reported a position in Lineage Cell Therapeutics in Q1 2019 and held it in 2 quarters.
  • Braun-Bostich & Associates's Lineage Cell Therapeutics position peaked at $0 in Q2 2019.
  • 96 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2019.

Based on Braun-Bostich & Associates's 13F filing for Q3 2019, filed 14 Nov 2019.